BrightSpring Health Services, I (BTSG) Stock Analysis

Q: What is the BTSG stock price target?

Take-profit $47.34 (+0.2% upside). Prior stop was $44.28.

Q: What are the risks of investing in BTSG?

Concentration risk — Customer: Medicare and Medicaid; Target reached (0.2% upside); Quality below floor (2.7 < 4.0); Target reached (0.2% upside); Quality below floor (2.7 < 4.0).

Q: Is BTSG overvalued or undervalued?

BrightSpring Health Services, I trades at a P/E of 100.3 (forward 24.6). TrendMatrix value score: 5.3/10. Overall verdict: Sell.

Q: What do analysts say about BTSG?

22 analysts cover BTSG with a consensus score of 4.3/5. Average price target: $53.

Range Bound setup

SellModerate ConfidenceUpdated 2026-05-01

Healthcare · Health Information Services

Earnings in 1 day (2026-05-01). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Engine safety override at $47.16: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: Elevated put/call ratio: 5.83; Below-average business quality.

BrightSpring Health Services is a home and community-based healthcare platform serving over 465,000 patients daily across all 50 states through Pharmacy Solutions and Provider Services segments. Revenue derives primarily from Medicare, Medicaid, and commercial insurance... Read more

$47.16+0.2% A.UpsideScore 5.5/10#8 of 13 Health Information Services

Stop $44.28Target $47.34(analyst − 10%)A.R:R 0.0:1

Analyst target$52.60+11.5%15 analysts

$47.34our TP

$47.16price

$52.60mean

$45

$60

Passes 5/7 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 1d<=7d. Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Concentration risk — Customer: Medicare and Medicaid

Target reached (0.2% upside)

Quality below floor (2.7 < 4.0)

Key Metrics

P/E (TTM)100.3

P/E (Fwd)24.6

Mkt Cap$9.3B

EV/EBITDA25.8

Profit Mgn1.5%

ROE5.9%

Rev Growth29.3%

Beta2.05

DividendNone

Rating analysts22

Quality Signals

Piotroski F7/9

Options Flow

P/C5.83bearish

IV98%elevated

Max Pain$30-36.4% vs spot

Concentration Risks(10-K Item 1A)

HIGHCustomerMedicare and Medicaid
10-K Item 1A: 'We derive substantial revenue from government healthcare programs, primarily Medicare and Medicaid'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value5.315%0.79

Quality2.715%0.41

Growth9.815%1.47

Momentum6.510%0.65

Sentiment7.010%0.70

Insider Activity3.010%0.30

Peer Rank4.510%0.45

Technical Setup4.95%0.25

Risk Profile3.45%0.17

Catalyst6.75%0.34

Overall (Σ contributions)5.52

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Gross Margin

0.0

Fcf Quality

0.0

Net Margin

0.7

Operating Margin

1.2

Roe

2.0

Roa

2.2

Moat

5.0

Current Ratio

5.7

Piotroski F

7.8

Earnings quality RED FLAG: -176% FCF/NINo competitive moatStrong Piotroski F-Score: 7/9Quality concerns

GatesA.R:R 0.0 < 1.5@spotEARNINGS PROXIMITY 1d<=7dMomentum 6.5>=5.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARRange BoundSuitability: Aggressive

RSI

60 · Neutral

↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $40.41Resistance $48.97

Price Targets

$44

$47

A.Upside+0.4%

A.R:R0.0:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Target reached (0.2% upside)

! Quality below floor (2.7 < 4.0)

! Reward/Risk 0.0:1 at current price — below 1.5:1 minimum

Earnings

3/4 beats

Next Earnings2026-05-01 (1d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is BTSG stock a buy right now?

Sell if holding. Engine safety override at $47.16: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: Elevated put/call ratio: 5.83; Below-average business quality. Chart setup: RSI 60 mid-range, Bollinger mid-band. Prior stop was $44.28. Score 5.5/10, moderate confidence.

What is the BTSG stock price target?

Take-profit target: $47.34 (+0.2% upside). Prior stop was $44.28. Stop-loss: $44.28.

What are the risks of investing in BTSG?

Concentration risk — Customer: Medicare and Medicaid; Target reached (0.2% upside); Quality below floor (2.7 < 4.0).

Is BTSG overvalued or undervalued?

BrightSpring Health Services, I trades at a P/E of 100.3 (forward 24.6). TrendMatrix value score: 5.3/10. Verdict: Sell.

What do analysts say about BTSG?

22 analysts cover BTSG with a consensus score of 4.3/5. Average price target: $53.

What does BrightSpring Health Services, I do?BrightSpring Health Services is a home and community-based healthcare platform serving over 465,000 patients daily...